Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Viloxazine Hydrochloride Patent Expiration

Viloxazine Hydrochloride is Used for managing symptoms of ADHD. It was first introduced by Supernus Pharmaceuticals Inc in its drug Qelbree on Apr 2, 2021.


Viloxazine Hydrochloride Patents

Given below is the list of patents protecting Viloxazine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Qelbree US11324753 Method of treatment of attention deficit/hyperactivity disorder (ADHD) Sep 04, 2029 Supernus Pharms
Qelbree US11458143 Method of treatment of attention deficit/hyperactivity disorder (ADHD) Sep 04, 2029 Supernus Pharms
Qelbree US9358204 Formulations of viloxazine Feb 07, 2033 Supernus Pharms
Qelbree US9603853 Formulations of viloxazine Feb 07, 2033 Supernus Pharms
Qelbree US9662338 Formulations of viloxazine Feb 07, 2033 Supernus Pharms


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Viloxazine Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Viloxazine Hydrochloride.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 07 Dec, 2023 US9358204
transaction for FDA Determination of Regulatory Review Period 30 Nov, 2023 US9358204
transaction for FDA Determination of Regulatory Review Period 30 Nov, 2023 US9603853
transaction for FDA Determination of Regulatory Review Period 30 Nov, 2023 US9662338
transaction for FDA Determination of Regulatory Review Period 29 Nov, 2023 US9603853
Second letter to regulating agency to determine regulatory review period 21 Oct, 2022 US9358204
Second letter to regulating agency to determine regulatory review period 21 Oct, 2022 US9603853
Second letter to regulating agency to determine regulatory review period 21 Oct, 2022 US9662338
Recordation of Patent Grant Mailed 04 Oct, 2022 US11458143
Patent Issue Date Used in PTA Calculation 04 Oct, 2022 US11458143



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳